TARGETSPub Date : 2002-10-01DOI: 10.1016/S1477-3627(02)02207-9
Hans Peter Fischer
{"title":"Turning quantity into quality: novel quality assurance strategies for data produced by high-throughput genomics technologies","authors":"Hans Peter Fischer","doi":"10.1016/S1477-3627(02)02207-9","DOIUrl":"10.1016/S1477-3627(02)02207-9","url":null,"abstract":"<div><p>The pharmaceutical industry is facing the challenge of managing the exponential increase in volume, diversity and complexity of data generated by high-throughput technologies such as genome sequencing, gene-expression profiling, protein-expression profiling, metabolic profiling and high-throughput screening. These novel ‘genomics’ technologies are expected to reshape the approach of life science companies to research. Unfortunately, in many cases genomics technologies have been used uncritically, and some preliminary results have been disappointing. The lack of standardized data validation and quality assurance processes is recognized as one of the major hurdles for successfully implementing genomics technologies. This is particularly important for industrialized drug discovery processes, because more and more key conclusions and far-reaching decisions in the pharmaceutical industry are based on data that is generated automatically. Therefore, automated, specialized quality-control systems that can spot erroneous data that might obscure important biological effects are needed urgently. In this article, special emphasis is placed on DNA microarray technologies, a key genomics technology that suffers from severe problems with data quality. A generic, automatable data-quality-assurance workflow is discussed that will ultimately improve the quality of the drug candidates and, at the same time, reduce overall drug-development costs.</p></div>","PeriodicalId":101208,"journal":{"name":"TARGETS","volume":"1 4","pages":"Pages 139-146"},"PeriodicalIF":0.0,"publicationDate":"2002-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1477-3627(02)02207-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78612385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
TARGETSPub Date : 2002-10-01DOI: 10.1016/S1477-3627(02)02206-7
Mark N. Namchuk
{"title":"Finding the molecules to fuel chemogenomics","authors":"Mark N. Namchuk","doi":"10.1016/S1477-3627(02)02206-7","DOIUrl":"10.1016/S1477-3627(02)02206-7","url":null,"abstract":"<div><p>Within the pharmaceutical industry, chemogenomics focuses on obtaining maximum benefit from the small molecules created in the drug-discovery process. Part of this discipline is the application of small-molecule inhibitors to aid in the characterization of the biological function of targets. The wider application of these approaches is hampered by a lack of reagents – that is, small molecules that have been thoroughly characterized and have appropriate potency and specificity for the target of interest. This review focuses on approaches used in the pharmaceutical industry to produce compounds for use in chemogenomics and on the challenges encountered in quickly characterizing their effects on biological activity.</p></div>","PeriodicalId":101208,"journal":{"name":"TARGETS","volume":"1 4","pages":"Pages 125-129"},"PeriodicalIF":0.0,"publicationDate":"2002-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1477-3627(02)02206-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77140519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
TARGETSPub Date : 2002-10-01DOI: 10.1016/S1477-3627(02)02211-0
Jack Elands
{"title":"About drugs and airplanes: will better use of data and information pave the road to success?","authors":"Jack Elands","doi":"10.1016/S1477-3627(02)02211-0","DOIUrl":"10.1016/S1477-3627(02)02211-0","url":null,"abstract":"","PeriodicalId":101208,"journal":{"name":"TARGETS","volume":"1 4","pages":"Pages 117-119"},"PeriodicalIF":0.0,"publicationDate":"2002-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1477-3627(02)02211-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"104409659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
TARGETSPub Date : 2002-10-01DOI: 10.1016/S1477-3627(02)02208-0
Nancy A. Hong, Steve A. Kay, Richard J. Glynne
{"title":"Using mouse forward genetics to define novel target space","authors":"Nancy A. Hong, Steve A. Kay, Richard J. Glynne","doi":"10.1016/S1477-3627(02)02208-0","DOIUrl":"10.1016/S1477-3627(02)02208-0","url":null,"abstract":"<div><p>Rapid advances in genomics technologies have identified a wealth of new therapeutic targets, but typically these targets are weakly validated with only circumstantial evidence to link them to human disease. The next challenge is testing gene-to-disease connections in a relevant animal model, a time-consuming and uncertain process using conventional reverse-genetic approaches such as knockout and transgenic mice. By contrast, forward genetics proceeds by measuring a physiological process that is relevant to disease, then identifying the gene products that impinge on this process. This ‘phenotype-first’ approach solves the bottleneck of target validation by using clinically relevant assays in a mammalian whole-animal system as a discovery platform. As an unbiased approach to gene discovery and validation, forward genetics will identify novel drug targets and increase the success rate of drug development.</p></div>","PeriodicalId":101208,"journal":{"name":"TARGETS","volume":"1 4","pages":"Pages 130-138"},"PeriodicalIF":0.0,"publicationDate":"2002-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1477-3627(02)02208-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90869522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
TARGETSPub Date : 2002-09-01DOI: 10.1016/S1477-3627(02)02202-X
Paul Thacker (freelance writer)
{"title":"Aromatase and COX-2 in the anti-cancer loop","authors":"Paul Thacker (freelance writer)","doi":"10.1016/S1477-3627(02)02202-X","DOIUrl":"10.1016/S1477-3627(02)02202-X","url":null,"abstract":"","PeriodicalId":101208,"journal":{"name":"TARGETS","volume":"1 3","pages":"Pages 85-86"},"PeriodicalIF":0.0,"publicationDate":"2002-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1477-3627(02)02202-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79471986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}